Pure Active Enoxolone 2%

• Limits the appearance of redness after an SLS-induced irritation ⁽¹⁾.
• IN-SKIN patented technology: diffusion booster to deliver the active ingredient exactly where it needs to go, with a X3 improvement of Pure Active diffusion into the skin ^(2).
• Quick penetration and non-oily ⁽³⁾ Very well tolerated ⁽⁴⁾

1. Clinical test, 22 volunteers, 23 to 64 years old, all skin types. 18 hours after wearing an occlusive patch containing the product + SLS or base + SLS and 6 hours after patch removal, 24 hours. Spectrophotometry.
2. Ex-vivo tests on Franz cells: comparison between the diffusion of a standard formula, containing IN-SKIN™ plus 2% caffeine (ingredient selected as example), and the diffusion of a standard formula containing only 2% caffeine (without IN-SKIN™)
3. Use test under dermatological control, 30 volunteers,36 to 70 years old, 100% sensitive skin. Twice-daily application on the face, 28 days. Self-assessment. 
4. Clinical assessment of tolerance under dermatological control, 30 volunteers,36 to 70 years old, 100% sensitive skin. Twice-daily application on the face, 28 days.

> CLINICAL RESULTS 

• Enoxolone 2%, limits the appearance of redness after an SLS-induced irritation:  
  • -11%*** in a* parameter increase vs. placebo (a* increases in response to irritation).  
  • -25%*** in L* parameter decrease (L* decrease in response to irritation).  

• Published study (Choi et al., 2024): Etat Pur Enoxolone 2% improves recovery (reducing erythema and pain) following laser procedures. 

  • 30 min post-procedure: -20.8%*** in Clinician Erythema Assessment scale (CEA) and  - 48%*** in Pain Visual Analog Scale (VAS) versus control.

  • 60min post-procedure : -42%*** in CEA 

  • 24 hrs post-procedure:-63%*** in CEA
    
    

    The efficacy of enoxolone in reducing erythema and pain after laser treatment: A randomized split-face pilot study

> PATIENTS FEEDBACKS 

Immediately: 

• skin is less reactive (for 90% of subjects)⁽³⁾. 

• skin is more soothed (mentioned by 97% of subjects)⁽³⁾.  

After 28 days of twice daily application:  

• sensations of tightness are reduced (for 97% of subjects)⁽³⁾ 

• skin is more comfortable (for 100% of them)⁽³⁾

**p<0.01

***p<0.001 t-test or ANOVA test

1. Clinical test, 22 volunteers, 23 to 64 years old, all skin types. 18 hours after wearing an occlusive patch containing the product + SLS or base + SLS and 6 hours after patch removal, 24 hours. Spectrophotometry. 
2. Clinical test performed on 10 volunteers, 19 to 70 years. Hemiface study after laser procedure (with/without Enoxolone 2%). Assessment of EI (erythema index) with Mexameter, clinician’s erythema assessment (CEA) and Pain Visual analog scale (VAS) at 30min, 60min and 24h after laser procedure. Published in Choi SY, Koh YG, Roh YJ, Park KY. The efficacy of enoxolone in reducing erythema and pain after laser treatment: A randomized split-face pilot study. J Cosmet Dermatol. Published online April 15, 2024. doi:10.1111/jocd.16329 
3. Use test under dermatological control, 30 volunteers,36 to 70 years old, 100% sensitive skin. Twice-daily application on the face, 28 days. Self-assessment.